Esophagogastric Cancer (MSK, JCO Oncology Practice 2023)

Overview

Single-center retrospective cohort of 1,123 patients with esophagogastric cancer (EGC, STAD, ESCA, GEJ adenocarcinoma) treated at Memorial Sloan Kettering Cancer Center between 2005 and 2018. Designed to compare clinical and molecular characteristics of early-onset (age ≤50) vs. average-onset (age >50) EGC, integrating somatic and germline sequencing data. PMID:37699004

Composition

  • 1,123 patients total: early-onset n=219 (median age 43, range 18–50); average-onset n=904 (median age 67, range 50–94). PMID:37699004
  • Somatic profiling via MSK-IMPACT (IMPACT505) available for 902 patients (196 early-onset, 706 average-onset). PMID:37699004
  • Germline analysis using 76- to 88-gene MSK-IMPACT panel on 466 patients (116 early-onset, 350 average-onset). PMID:37699004
  • Cancer types: esophageal, gastroesophageal junction, and gastric adenocarcinoma. PMID:37699004

Assays / panels (linked)

Papers using this cohort

  • PMID:37699004 — Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer.

Notable findings derived from this cohort

  • Early-onset EGC had higher proportion of women (39% vs. 28%, P=0.002), gastric primary site (64% vs. 44%), and signet ring cell/diffuse-type histology (31% vs. 9%, P<0.0001). PMID:37699004
  • Early-onset tumors had lower TMB (median 3.3 vs. 4.9 mut/Mb, P<0.001) and lower fraction genome altered (0.055 vs. 0.132). PMID:37699004
  • CCNE1 alterations enriched in early-onset (16% vs. 7%, Q=0.011); CDH1 alterations enriched in early-onset (12% vs. 6%, Q=0.03); CDKN2A enriched in average-onset (22% vs. 11%). PMID:37699004
  • Multivariable analysis: CDKN2A alterations associated with worse survival (HR=1.55, P<0.001); ERBB2 associated with improved survival (HR=0.65, P=0.01). PMID:37699004

Sources

This page was processed by crosslinker on 2026-05-04.